Bessemer Group’s Agios Pharmaceuticals AGIO Stock Holding History

Bessemer Group’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3K	Hold	76	–	–	﹤0.01%	2333
2026 Q1	$3K	Hold	76	–	–	﹤0.01%	2296
2025 Q4	$2K	Sell	76 -110	-59%	-$3.86K	﹤0.01%	2381
2025 Q3	$7K	Buy	186 +76	+69%	+$2.86K	﹤0.01%	2042
2025 Q2	$4K	Hold	110	–	–	﹤0.01%	2054
2025 Q1	$3K	Sell	110 -10	-8%	-$332	﹤0.01%	2125
2024 Q4	$4K	Hold	120	–	–	﹤0.01%	2033
2024 Q3	$5K	Buy	+120	New	+$5.45K	﹤0.01%	1895
2019 Q4	–	Sell	-23	Closed	-$1K	–	1619
2019 Q3	$1K	Buy	+23	New	+$952	﹤0.01%	1641
2018 Q2	–	Sell	-107	Closed	-$9K	–	1664
2018 Q1	$9K	Hold	107	–	–	﹤0.01%	1495
2017 Q4	$6K	Hold	107	–	–	﹤0.01%	1539
2017 Q3	$7K	Hold	107	–	–	﹤0.01%	1622
2017 Q2	$6K	Hold	107	–	–	﹤0.01%	1650
2017 Q1	$6K	Hold	107	–	–	﹤0.01%	1582
2016 Q4	$4K	Hold	107	–	–	﹤0.01%	1767
2016 Q3	$6K	Hold	107	–	–	﹤0.01%	1600
2016 Q2	$4K	Hold	107	–	–	﹤0.01%	1193
2016 Q1	$4K	Hold	107	–	–	﹤0.01%	1283
2015 Q4	$7K	Hold	107	–	–	﹤0.01%	1284
2015 Q3	$8K	Buy	+107	New	+$10.5K	﹤0.01%	1239

Other funds holding AGIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Bessemer Group's AGIO Position: Q2 2026 in Review

Bessemer Group held its Agios Pharmaceuticals (AGIO) position steady in Q2 2026 at 76 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #2333.

Bessemer Group first reported a position in AGIO in Q3 2015 and has held it in 20 quarters since. The position peaked at $9K in Q1 2018. 239 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

Bessemer Group held 76 shares of Agios Pharmaceuticals worth $3K as of Q2 2026.
Bessemer Group left its Agios Pharmaceuticals share count unchanged in Q2 2026.
Agios Pharmaceuticals made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2333 holding.
Bessemer Group first reported a position in Agios Pharmaceuticals in Q3 2015 and has held it in 20 quarters since.
Bessemer Group's Agios Pharmaceuticals position peaked at $9K in Q1 2018.
239 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.